Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026)

Kiniksa Pharmaceuticals International's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $190.0 million for Q1 2026.

• Quarterly Cash & Equivalents fell 29.21% year-over-year to $190.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.0 million (down 29.21% YoY) and the FY2025 annual result came in at $165.6 million, down 9.8% from the prior year.
• Cash & Equivalents was $190.0 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $165.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $352.1 million in Q3 2025 and bottomed at $80.6 million in Q1 2023.
• A 5-year average of $183.3 million and a median of $183.6 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 44.62% — and 2024, when it soared 94.34%.
• Kiniksa Pharmaceuticals International's Cash & Equivalents stood at $122.7 million in 2022, then dropped by 12.03% to $108.0 million in 2023, then jumped by 70.05% to $183.6 million in 2024, then decreased by 9.8% to $165.6 million in 2025, then increased by 14.71% to $190.0 million in 2026.
• Business Quant data shows KNSA's Cash & Equivalents at $190.0 million in Q1 2026, $165.6 million in Q4 2025, and $352.1 million in Q3 2025.